New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ACAD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
09:40 EDTACADACADIA U.S. introduction of Nuplazid likely in 2016, says Ladenburg
Subscribe for More Information
07:04 EDTACADACADIA submits NDA for Nuplazid for treatment of Parkinson's Disease psychosis
Subscribe for More Information
07:04 EDTACADACADIA names Steve Davis president, CEO
ACADIA Pharmaceuticals announced that its Board of Directors has appointed Steve Davis as President and CEO. Davis has been serving as ACADIA's Interim Chief Executive Officer since March 2015. Davis has also been appointed to the ACADIA Board of Directors.
August 27, 2015
10:00 EDTACADOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:37 EDTACADACADIA upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
August 25, 2015
09:59 EDTACADOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:07 EDTACADACADIA initiated with a Buy at Aegis
Subscribe for More Information
August 21, 2015
16:38 EDTACADACADIA unit manufacturing agreement with BASF Pharma
On August 17, our Swiss subsidiary, ACADIA Pharmaceuticals GmbH, entered into a co-operation agreement and product schedule, collectively referred to as the manufacturing agreement, with BASF Pharma SA, or BASF. Under the manufacturing agreement, BASF has agreed to manufacture and supply pimavanserin tartrate, the active pharmaceutical ingredient of NUPLAZID, for commercial use. The term of the manufacturing agreement extends through December 31, 2020 and will automatically renew for subsequent one year terms unless either party provides timely notice of its intent not to renew, or unless the manufacturing agreement is terminated earlier pursuant to its terms.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use